Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial.
Authors
Shitara, KÖzgüroğlu, M
Bang, Y
Bartolomeo, M
Mandalà, M
Ryu, M
Fornaro, L
Olesiński, T
Caglevic, C
Chung, H
Muro, K
Goekkurt, E
Mansoor, Was
McDermott, R
Shacham-Shmueli, E
Chen, X
Mayo, C
Kang, S
Ohtsu, A
Fuchs, C
Affiliation
National Cancer Center Hospital East, Kashiwa, JapanIssue Date
2018-06-04
Metadata
Show full item recordAbstract
Patients with advanced gastric or gastro-oesophageal junction cancer that progresses on chemotherapy have poor outcomes. We compared pembrolizumab with paclitaxel in patients with advanced gastric or gastro-oesophageal junction cancer that progressed on first-line chemotherapy with a platinum and fluoropyrimidine.Citation
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. 2018, LancetJournal
LancetDOI
10.1016/S0140-6736(18)31257-1PubMed ID
29880231Type
ArticleLanguage
enISSN
1474-547Xae974a485f413a2113503eed53cd6c53
10.1016/S0140-6736(18)31257-1